Eli Lilly and Company (NYSE:LLY) Stock Unloaded Rep. Julie Johnson

Representative Julie Johnson (D-Texas) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on January 15th, the Representative disclosed that they had sold between $1,001 and $15,000 in Eli Lilly and Company stock on December 18th. The trade occurred in the Representative’s “CHASE BROKERAGE ACCOUNT (3935)” account.

Representative Julie Johnson also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of General Dynamics (NYSE:GD) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Dover (NYSE:DOV) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Philip Morris International (NYSE:PM) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Johnson & Johnson (NYSE:JNJ) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Bank of America (NYSE:BAC) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Walmart (NASDAQ:WMT) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Republic Services (NYSE:RSG) on 12/18/2025.

Eli Lilly and Company Stock Up 0.5%

Shares of NYSE:LLY traded up $5.29 during midday trading on Friday, reaching $1,038.26. The company had a trading volume of 3,816,482 shares, compared to its average volume of 2,367,384. The stock has a market capitalization of $981.55 billion, a P/E ratio of 50.80, a PEG ratio of 0.75 and a beta of 0.35. The stock’s fifty day moving average price is $1,051.34 and its 200-day moving average price is $870.84. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The business had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. During the same period in the prior year, the firm earned $1.18 EPS. The business’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company’s payout ratio is 29.35%.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Howard Capital Management Group LLC lifted its position in Eli Lilly and Company by 116.1% during the fourth quarter. Howard Capital Management Group LLC now owns 1,660 shares of the company’s stock worth $1,784,000 after acquiring an additional 892 shares during the last quarter. StoneCrest Wealth Management Inc. raised its holdings in shares of Eli Lilly and Company by 4.6% during the 4th quarter. StoneCrest Wealth Management Inc. now owns 6,598 shares of the company’s stock worth $7,091,000 after buying an additional 291 shares in the last quarter. MRA Advisory Group boosted its stake in shares of Eli Lilly and Company by 17.5% in the 4th quarter. MRA Advisory Group now owns 986 shares of the company’s stock valued at $1,060,000 after purchasing an additional 147 shares in the last quarter. Bouchey Financial Group Ltd boosted its holdings in shares of Eli Lilly and Company by 3.1% during the 4th quarter. Bouchey Financial Group Ltd now owns 1,123 shares of the company’s stock valued at $1,207,000 after acquiring an additional 34 shares in the last quarter. Finally, Aspire Capital Advisors LLC grew its holdings in shares of Eli Lilly and Company by 3.3% during the fourth quarter. Aspire Capital Advisors LLC now owns 527 shares of the company’s stock worth $566,000 after purchasing an additional 17 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Nvidia partnership — Lilly and Nvidia announced a joint $1 billion lab to build and equip an AI-enabled research facility, signaling long-term R&D acceleration and potential productivity gains for drug discovery. Nvidia and Eli Lilly Are Partnering on a $1 Billion Lab. Here’s What Investors Need to Know.
• Positive Sentiment: Pipeline progress — Lilly reported completion of a Phase 1 study in China for a new oral candidate, advancing its oral-GLP1 pipeline and de‑risking future regulatory steps outside the U.S. Eli Lilly Quietly Advances New Oral Candidate With Completion of Phase 1 Study in China
• Positive Sentiment: Oral and oncology R&D signals — Updates on olomorasib capsule study and a Japanese Phase 1 combo trial for next‑wave obesity drugs show steady, diversified pipeline momentum beyond current GLP‑1 franchises. Eli Lilly’s Olomorasib Capsule Study Signals Steady Pipeline Progress for Investors Lilly Advances Next-Wave Obesity Pipeline With Japanese Phase 1 Combo Study
• Positive Sentiment: Analyst backing and strategic focus — JPMorgan highlights cardiovascular Lp(a) programs and analysts (e.g., Jefferies) maintain bullish targets, reinforcing the growth narrative beyond obesity drugs. JPM26: Eli Lilly highlights Lp(a) drugs as cardiovascular growth focus
• Neutral Sentiment: Pre-earnings momentum — Market indicators show strong momentum and high analyst interest ahead of upcoming earnings, which can amplify intraday moves but increases dependence on the print. Eli Lilly Shares Near Highs As Score Flags Momentum Ahead Of Earnings
• Neutral Sentiment: Investor commentary — Several opinion pieces argue the recent dip is a buying opportunity given Lilly’s fundamentals; these help sentiment but are not new catalysts. Buy The Dip In LLY Stock?
• Negative Sentiment: FDA delay on oral obesity pill Orforglipron — Reports the regulator pushed its decision to April have pressured the stock by extending competitor advantage and delaying potential sales. LLY Stock Falls After FDA Reportedly Delays Obesity Drug Ruling
• Negative Sentiment: Antitrust/competition litigation — A compounding pharmacy sued Lilly and Novo Nordisk claiming coordinated efforts to limit compounding substitutes; litigation risk adds regulatory/legal uncertainty. Lilly, Novo sued over GLP‑1 drug dominance by compounding pharmacy

Analysts Set New Price Targets

Several analysts recently commented on LLY shares. Scotiabank initiated coverage on shares of Eli Lilly and Company in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $1,165.00 target price for the company. Leerink Partners set a $1,234.00 price target on Eli Lilly and Company in a research note on Monday, January 5th. Daiwa Capital Markets set a $1,230.00 price target on Eli Lilly and Company and gave the stock a “buy” rating in a research note on Tuesday, December 16th. Guggenheim reaffirmed a “buy” rating and issued a $1,163.00 price target on shares of Eli Lilly and Company in a research report on Wednesday, December 3rd. Finally, HSBC restated a “hold” rating and set a $1,070.00 price objective on shares of Eli Lilly and Company in a report on Wednesday, December 10th. Five equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, Eli Lilly and Company has a consensus rating of “Buy” and a consensus target price of $1,174.70.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.